Superluminal Medicines, Inc.

BiotechnologyBiotechnologyAI/MLDrug Discovery

📍 Boston, MA, United States• Founded 2022

StreetZero Signal 69

Be the first to signal interest

About Superluminal Medicines, Inc.

Superluminal Medicines, Inc. is a Boston-based drug discovery company that integrates AI/ML, protein dynamics, and structural biology to develop small molecule therapeutics for cardiometabolic diseases. The company, known as 'The Membrane Company,' uses generative biology, chemistry, and machine learning approaches to accelerate medicine creation, with a focus on high-value G protein-coupled receptor targets. It launched in 2022 and has advanced programs into clinical development, including a collaboration with Eli Lilly.

LATEST FUNDINGPrivate Placement

$65.5M

Announced 2026-09-03

TOTAL RAISED$158M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Superluminal Medicines, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2022

HQBoston, MA, United States

Industry

Biotechnology

Investors

RA Capital Management Insight Partners NVentures Gaingels Catalio Capital Management

Key highlights

Closed $120M Series A in September 2024 led by RA Capital to advance lead programs.
Announced $60M Series B to move MC4R agonist into clinic for rare obesity forms.
Total funding exceeds $153M across seed, Series A, and Series B rounds.
Partnered with Eli Lilly for GPCR targets with up to $1.3B in potential milestones.
Employs 29 people and focuses on cardiometabolic diseases using generative approaches.